The dose-response curve is one of the main pharmacological characteristics of a drug, and is one of the main determinants of how that drug will be used in therapeutics. Most drugs approximate to the familiar S-shaped dose-response curve of the pharmacologist, with a zone at a very low dose when there is no discernible effect followed by a zone where there is an increasing effect, and the relationship is usually roughly linear between the response, plotted arithmetically, and the dose, plotted logarithmically. At the high part of -the range there is usually a flattening out when the maximum is achieved. What is crucial is the slope of that part of the curve lying between the zone where nothing happens and the zone where a flat maximum has been reached.
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In the field of hypertension, guanethidine and prazosin are examples of drugs with a fairly steep dose-response curve, and drugs with the property of causing dilatation of the veins are particularly likely to have a very steep dose-response curve in the standing position because the blood pressure may tend to go down to zero. A steep doseresponse curve, coupled with a high degree of individual variability, means that the dose must be individually adjusted and relatively large changes in response may occur as a result of doubling the dose, omitting doses or errors in prescribing or deliberate overdose. The benzothiadiazine diuretics are examples of drugs which have a relatively flat dose-response curve and this was established a long time ago, by a study done by Cranston at Oxford, amongst others. The advantage of a flat dose-response curve is that the adjustment of dose is no longer critical and it may be possible to think in terms of a fixed dose for most patients, which is how thiazide diuretics are usually used. The dose-response curve for thiazides is not perfectly flat, nor is it for atenolol. If a flat dose-response curve is desired it may be achieved by the inherent pharmacological characteristics of the drug, or it may be possible to use the drug in a supramaximal dose. This is the way in which antibiotics are normally used, for example benzyl penicillin in the treatment of a Gram-positive infection.
It would be unwise to assume that the doseresponse curve to one kind of action, e.g. blockade of exercise tachycardia, and the dose-response curve to another kind of action, e.g. control of the supine blood pressure, will be exactly the same; indeed there are many grounds for believing that it would not be the same. For example, in a study in our laboratory a 200 mg oral dose of atenolol was given and the fall-off of the blockade of exercise tachycardia was as follows: 37 % blockade at 2 hours, 30% at 11 hours and 14% at 27 hours. But the blockade of systolic blood pressure on exercise fell off in a different fashion: 36 % blockade at 2 hours (about the same as the blockade of exercise tachycardia), 240% at 11 hours, but only 50% blockade at 27 hours (as against a 140% blockade of the exercise tachycardia response). So it is important to realize that a dose-response curve may not be exactly the same for all parameters.
The method of deriving a dose-response curve is obviously straightforward if the effect of a drug is immediate. A series of doses of the drug is given, either in incremental or random order, and the relationship between observed effect and log dose plotted. This is difficult to plot for the hypotensive effect of a beta-receptor blocking drug. Because there is some argument about how quickly the full effect is seen, and under these circumstances the best way of deriving a doseresponse curve is not by single dose administration but by chronic administration. The data on the dose-response relationship with atenolol are quite brief, and were derived from a study involving a group of 18 patients who were titrated with doses between 75 and 900 mg daily. Not all of them covered the whole dose range because, if an adequate effect or side effects developed, the dosage was held at a lower rate and the patients entered a double-blind, randomized, controlled crossover trial.
Fig I shows the supine and erect blood pressures in a group of 9 patients who all had four dosages, 75, 150, 300 and 600 mg of atenolol, each dosage for a two-week period. The comparison is not with placebo blood pressure, but with the pretreatment pressure. Looking at the blood pressures over the 75, 150 and 300 mg dose arterialpressure range there is a small progressive decrease, but between 300 and 600 the means showed an upward turn. The difference between 300 and 600 mg was interesting but not significant and may have been due to chance. There have been reports with some other beta-blocking drugs, most notably with pindolol (Visken), that there may be an inappropriate elevation of blood pressure beginning to appear at high doses, but pindolol is a drug with more partial agonist activities (ISA) than any of the other betareceptor blocking drugs, and the high-dose effect with pindolol may be simply due to sympathetic stimulation. However, as atenolol does not have an appreciable ISA effect this would not provide an explanation. Dr Hansson using doses of 100, 200 and 400 mg also found this to be the case, the falls in blood pressure compared with placebo being 17/11 mmHg with 100 mg, 21/15 mmHg with 200 mg and 28/18 mmHg with 400 mg/day. Thus the dose-response relationship with atenolol is relatively flat, but not perfectly so, over the range of 75 to 300 mg/day and the range used by Dr Hansson of 100 to 400 mg/day. Both sets of data indicate that there is some additional effect from increasing the dose within the range of 100 to 400 mg or 75 to 300 mg but the additional effect is of the same order as, for example, increasing the dose of bendrofluazide from 5 to 10 mg/day. So there is some justification for using a fixed dose in most patients, with a small additional effect by increasing the dose to a maximum of 300 or 400 mg/day. As a drug is eliminated from the body after administration the dose-response curve is in effect being shifted towards the origin. When half the drug has been eliminated it is much the same as looking at the response to half the admirnistered dose. It would therefore be unwise to assume that there is a linear relationship between the elimination of the drug from the body and the effect, because there is not necessarily a linear relationship between the dose and the effect. A very good example of this is propranolol. The plasma half-life of a 200 mg dose of propran-olol is about four hours if the concentration of the drug is measured in the plasma. But if the half-life of the blockade of exercise tachycardia is measured it comes out at about 10 or 11 hours, and if the duration of the hypotension is looked at, the half-life is even longer.
Normotensive volunteers have been used in recent years to study the hypotensive effects of many drugs such as methyldopa, clonidine, propranolol and atenolol. Contrary to what is often said, it is quite easy, if proper experimental conditions are used, to observe blood pressure lowering effects in normal people, although they are of lesser magnitude than in hypertensives.
In such a study 5 normotensive volunteers were given a single 100 mg dose of atenolol and the 24-hour values (means and standard errors) for heart rate, systolic and diastolic blood pressure were measured. The slowing of heart rate was still evident at 24 hours and the reduction in diastolic pressure beyond three hours was statistically significant. The separation of response to atenolol and placebo, although not great, was about 10 mmHg, which is much the same as the difference in diastolic pressure observed in some of the randomized control trials in hypertensives when placebo and beta blocking drugs have been compared. The fall of blood pressure reached maximum at around 5 hours and then did not change much up to about 24 hours.
In summary, atenolol is a drug which has a relatively flat dose-response curve, at least in the range of dose between 75 and 300 mg/day. There is therefore some justification for using a single fixed dose once per day. That fixed dose would seem to be somewhere in the range of 75 to 100 mg/day. The flat dose-response curve is also a contributory factor to a long duration of action. Other contributing factors to that include the plasma half-life of the drug, which is also relatively long compared with other beta-blocking drugs. In terms of control of supine arterial pressure this provides a justification for oncedaily dosing.
